Fatty Liver News and Research

Latest Fatty Liver News and Research

Mouse study shows regular exercise reduces the chance of developing liver cancer

Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC).

26 Apr 2013

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

26 Apr 2013

GI nematode infections combat obesity and improve related metabolic disorders

Researchers at the University of Maryland School of Medicine, Baltimore, have shown in a mouse model that infection with nematodes (also known as roundworms) can not only combat obesity but ameliorate related metabolic disorders.

26 Apr 2013

Research reveals deadly impact of alcohol and body weight on liver disease

Research announced today at the International Liver CongressTM 2013 has revealed the deadly impact that alcohol and body weight have on liver disease.

25 Apr 2013

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin Ronis have determined that dietary substitution of saturated fats enriched in medium chain triglycerides (MCT) for polyunsaturated fat prevents the development of nonalcoholic fatty liver disease (NAFLD).

25 Apr 2013

Study identifies gene variants associated with histological features of NAFLD

More patients could be diagnosed earlier with non-alcoholic fatty liver disease after a cohort study presented at the International Liver Congress 2013 identified variants within four genes significantly associated with the histological features of the disease.

24 Apr 2013

Researchers uncover potential new way to fight obesity-related illness

A potential new way to fight obesity-related illness has been uncovered, thanks to serendipitous research led by investigators at the Case Western Reserve University School of Medicine.

24 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

Imbalance between neutrophil elastase and α1-antitrypsin leads to obesity, inflammation

Many recent studies have suggested that obesity is associated with chronic inflammation in fat tissues. Researchers at Sanford-Burnham Medical Research Institute have discovered that an imbalance between an enzyme called neutrophil elastase and its inhibitor causes inflammation, obesity, insulin resistance, and fatty liver disease.

3 Apr 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013

Deleting Plin2 gene prevents obesity in mice

Researchers have discovered that deleting a specific gene in mice prevents them from becoming obese even on a high fat diet, a finding they believe may be replicated in humans.

6 Mar 2013

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.

12 Feb 2013

MRI promising for noninvasive hepatic steatosis assessment

Magnetic resonance imaging allows accurate measurement of the extent and severity of hepatic steatosis in patients with nonalcoholic fatty liver disease, demonstrate the results of two studies published in Radiology.

11 Feb 2013

Amlexanox also reverses obesity, diabetes and fatty liver in mice

Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.

11 Feb 2013

Donor liver quality: an interview with Dr Eric Orman

Liver transplantation is a surgical procedure in which a liver (or part of a liver) is removed from a donor and placed into a recipient. Although some transplants use a portion of the liver of living donors, the vast majority of donors are deceased.

6 Feb 2013

DHA more effective than EPA in preventing liver inflammation and fibrosis

Research at Oregon State University has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis - common problems that are steadily rising along with the number of Americans who are overweight.

6 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

TSC22D4 gene plays a key role in the onset of cachexia

Cachexia or wasting is a condition affecting up to 70 percent of cancer patients, depending on the type of cancer. It is characterized by a dramatic loss of body weight that is independent of food intake. Cachexia is seen particularly often and most pronounced in patients suffering from cancers of the digestive tract and the lungs.

16 Jan 2013

SR9238 compound can reverse effects of fatty liver disease

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed the first synthetic compound that can reverse the effects of a serious metabolic condition known as fatty liver disease. True to its name, the disease involves an abnormal buildup of fat in the liver.

20 Dec 2012

LSUHSC to advance research on social, genetic, environmental and behavioral determinants of future obesity

Melinda Sothern, PhD, CEP, Professor and Director of the Behavioral and Community Health Sciences Program at LSU Health Sciences Center New Orleans School of Public Health, has been awarded $675,000 in grant funding to advance her research on the role of social, genetic, environmental and behavioral determinants of future obesity.

7 Dec 2012